Financial Expectations for 2025
All line items are according to GAAP, except as otherwise noted.
| In millions | 2025 Expectations | |
| Total Revenues | $1,340 – $1,430 | |
| VIVITROL Net Sales | $440 – $460 | |
| ARISTADAi Net Sales | $335 – $355 | |
| LYBALVI Net Sales | $320 – $340 | |
| Cost of Goods Sold | $185 – $205 | |
| R&D Expenses | $305 – $335 | |
| SG&A Expenses | $655 – $685 | |
| GAAP Net Income a | $175 – $205 | |
| EBITDA | $215 – $245 | |
| Adjusted EBITDA | $310 – $340 | |
| Effective Tax Rate | ~17% |
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。